NEW YORK (360Dx) – Paris-based Sebia said today that it has inked an agreement with Janssen Biotech to develop an in vitro diagnostic test that mitigates potential interference during immunofixation electrophoresis tests that measure a patient’s response to Darzalex (daratumumab), Janssen’s FDA-approved monoclonal antibody used to treat multiple myeloma.

Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.